Evidence map›Paper›PMID 35958243›Full record

ArticleLeukemia research reports2022

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation.

R Iannotta, M Celentano, S Marotta, C M Pedata, C Riccardi, I Migliaccio, A Viola, S M Muggianu, C Falco, D Bovenzi and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

R IannottaStem Cell Transplant Program, AORN Cardarelli, Naples, Italy.
M CelentanoStem Cell Transplant Program, AORN Cardarelli, Naples, Italy.
S MarottaStem Cell Transplant Program, AORN Cardarelli, Naples, Italy.
C M PedataStem Cell Transplant Program, AORN Cardarelli, Naples, Italy.
C RiccardiStem Cell Transplant Program, AORN Cardarelli, Naples, Italy.
I MigliaccioStem Cell Transplant Program, AORN Cardarelli, Naples, Italy.
A ViolaHematology, AORN Cardarelli, Naples, Italy.
S M MuggianuStem Cell Transplant Program, AORN Cardarelli, Naples, Italy.
C FalcoTransfusion Medicine Service, AORN Cardarelli, Naples, Italy.
D BovenziTransfusion Medicine Service, AORN Cardarelli, Naples, Italy.
F FerraraHematology, AORN Cardarelli, Naples, Italy.
A PicardiStem Cell Transplant Program, AORN Cardarelli, Naples, Italy.
Ospedale Antonio Cardarelli · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Case of a patient with acute myeloid leukemia (AML) positive for mutations in both genes NPM1 and FLT3-ITD who underwent two allogeneic haematopoietic stem cell transplants (HSCT); the second allograft one was followed by extramedullary relapse (granulocytic sarcoma of right breast), with blast cells positive for FLT3-ITDmutation.  Treatment with Gilteritinib, a second generation selective oral type I FLT3 inhibitor, was started after the second HSCT with complete regression of breast granulocytic sarcoma in absence of hematological and extra hematologic toxicity. We conclude that Gilteritinib can represent an effective therapy for extra hematologic relapse, with acceptable toxicity and outpatient management.

Indexed as

Acute myeloid leukemia FLT3 ITD positiveExtramedullary relapse FLT3 ITD positiveGilteritinibHSCT allogeneic haematopoietic stem cell transplants

Identifiers

PMID35958243
PMCPMC9358450
OpenAlexW4288046903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.